Other News To Note
Nektar Therapeutics Inc., of San Francisco, said preclinical data were reported at the Society for Neuroscience meeting in New Orleans for NKTR-171, a sodium channel blocker to treat neuropathic pain.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.